Relmada Therapeutics (RLMD) announced the appointment of Max Kates, MD, Associate Professor of Urology and Oncology at Johns Hopkins University School of Medicine, to Relmada’s Clinical Advisory Board to support the development of NDV-01 for the potential treatment of non-muscle invasive bladder cancer. Relmada intends to initiate the Phase 3 program for NDV-01 in H1 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLMD:
- Relmada Therapeutics Updates Corporate Presentation on NDV-01
- Relmada Therapeutics regains compliance with Nasdaq min bid price requirement
- Relmada Therapeutics Regains Nasdaq Compliance
- Relmada Therapeutics Highlights Strategic Progress to Shareholders
- Relmada Therapeutics CEO remains ‘optimistic’ about company’s future